NY-ESO-1 expression and immunogenicity in prostate cancer patients

##plugins.themes.academic_pro.article.sidebar##

Published Oct 31, 2011
Download
pdf
Vol. 89 No. 10 (2011): Issue Oct 2011

##plugins.themes.academic_pro.article.main##

Asma Gati
Nesrine Lajmi
Amine Derouiche
Raja Marrakchi
Mohamed Chebil
Amel Benammar-Elgaaied

Abstract

Background: Prostate cancer is the second leading cause of men cancer-related death. Cancer immunotherapy has been investigated as a treatment which might be instituted at the point of detection of androgen-independent metastatic disease.
Aim: to investigate the expression and humoral response against NYESO-1 in patients with prostate cancer (PC) and to analyze the relationship between expression of NY-ESO-1 and clinicopathological features.
Methods: NY-ESO-1 mRNA in surgically resected PC and benign prostatic hyperplasia (BPH) were examined by reverse transcriptionpolymerase chain reaction. The antibody response to NY-ESO-1 was examined by enzyme-linked Elisa assay using recombinant NYESO-1 protein.
Results: NY-ESO-1 mRNA was detected in 9 of 23 (39%) PC patients. Antibodies against NY-ESO-1 protein were detected in 12 of 23 (52%) sera of PC patients and in 5 of 9 (55%) of NY-ESO-1 expressing tumors. However, no mRNA copy or NY-ESO-1 antibodies were detected in all BPH patients tested.
Conclusion : The present study has demonstrated the expression of NY-ESO-1mRNA in prostate Cancer patients and NY-ESO-1 antibody production. Our data suggest that NY-ESO-1 could be used as a tumor marker and constitute a good candidate for vaccine-based immunotherapy for hormonal resistant prostate cancer patients.

Keywords:

Cancer testis antigen- Immunotherapy- NY-ESO-1- Prostate cancer

##plugins.themes.academic_pro.article.details##

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M J. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
  2. Hadaschik B A, Gleave M E. Therapeutic options for hormonerefractory prostate cancer in 2007. Urol Oncol 2007; 25:413-19.
  3. Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008; 14:4385-91.
  4. Wong M K. The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics. Curr Oncol Rep 2008; 10:259-63.
  5. Scanlan M J, Gure A O, Jungbluth A A, Old L J, Chen Y T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188:22-32.
  6. Jager E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000; 97:4760-65.
  7. Chen Y T, Scanlan M J, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94:1914-18.
  8. Sugita Y, Wada H, Fujita S, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer res 2004; 64:2199-204.
  9. Odunsi K, Jungbluth A A, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076-83.
  10. Zhang W M, Xiao G, Zhang M, Guo A L, Dong Y, Wen J M. [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma]. Zhonghua bing li xue za zhi Chinese journal of pathology 2005; 34:202-205.
  11. Konishi J, Toyooka S, Aoe M, et al. The relationship between NYESO- 1 mRNA expression and clinicopathological features in nonsmall cell lung cancer. Oncol Rep 2004; 11:1063-67.
  12. Fujita S, Wada H, Jungbluth AA, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004; 10:6551-58.
  13. Jager D, Stockert E, Karbach J, et al. Urine antibody against human cancer antigen NY-ESO-1. Cancer Immun 2002; 2:10.
  14. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006; 95:1-30.
  15. Dunn G P, Bruce A T, Ikeda H, Old L J, Schreiber R D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998.
  16. Stockert E, Jager E, Chen Y T, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187:1349-54.
  17. Gnjatic S, Atanackovic D, Jager E, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A 2003; 100:8862-67.
  18. Hudolin T, Juretic A, Spagnoli G C, et al. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NYESO- 1 in cancerous and benign prostatic tissue. The Prostate 2006; 66:13-18.
  19. Jungbluth AA, Antonescu C R, Busam K J, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001; 94:252-56.
  20. Juretic A, Spagnoli G C, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 2003; 4:104- 109.
  21. Kurashige T, Noguchi Y, Saika T, et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer res 2001; 61:4671-74.
  22. Fossa A, Berner A, Fossa S D, Hernes E, Gaudernack G, Smeland E B. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. The Prostate 2004; 59:440-47.
  23. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003; 3:10.